Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, Jiang Z, Jain D, Iozzo RV, Violette SM, Weinreb PH, Davis RJ, Gioeli D, FitzGerald TJ, Altieri DC, Languino LR.

Cancer Res. 2016 Sep 1;76(17):5163-74. doi: 10.1158/0008-5472.CAN-16-0543. Epub 2016 Jul 22.

2.

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.

Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Slingluff CL Jr, Abbas T.

EBioMedicine. 2016 Aug;10:85-100. doi: 10.1016/j.ebiom.2016.06.023. Epub 2016 Jun 16.

3.

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ.

Oncotarget. 2016 Jan 19;7(3):2734-53. doi: 10.18632/oncotarget.6548.

4.

Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA.

Zboray L, Pluciennik A, Curtis D, Liu Y, Berman-Booty LD, Orr C, Kesler CT, Berger T, Gioeli D, Paschal BM, Merry DE.

Cell Rep. 2015 Dec 15;13(10):2312-23. doi: 10.1016/j.celrep.2015.11.019. Epub 2015 Dec 7.

5.

Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Ta HQ, Ivey ML, Frierson HF Jr, Conaway MR, Dziegielewski J, Larner JM, Gioeli D.

Cancer Res. 2015 Dec 1;75(23):5093-105. doi: 10.1158/0008-5472.CAN-15-0224. Epub 2015 Nov 16.

6.

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.

PLoS One. 2015 Sep 25;10(9):e0138210. doi: 10.1371/journal.pone.0138210. eCollection 2015.

7.

Cell-cycle-dependent regulation of androgen receptor function.

Koryakina Y, Knudsen KE, Gioeli D.

Endocr Relat Cancer. 2015 Apr;22(2):249-64. doi: 10.1530/ERC-14-0549. Epub 2015 Feb 17.

8.

The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Oct;21(5):R395-407. doi: 10.1530/ERC-14-0217. Epub 2014 Aug 5. Review.

9.

p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.

Axelrod MJ, Gordon V, Mendez RE, Leimgruber SS, Conaway MR, Sharlow ER, Jameson MJ, Gioeli DG, Weber MJ.

Cell Signal. 2014 Aug;26(8):1627-35. doi: 10.1016/j.cellsig.2014.03.013. Epub 2014 Mar 21.

10.

Androgen receptor phosphorylation: biological context and functional consequences.

Koryakina Y, Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Aug;21(4):T131-45. doi: 10.1530/ERC-13-0472. Epub 2014 Jan 14. Review.

11.

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.

Axelrod M, Gordon VL, Conaway M, Tarcsafalvi A, Neitzke DJ, Gioeli D, Weber MJ.

Oncotarget. 2013 Apr;4(4):622-35.

12.

Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Roller DG, Axelrod M, Capaldo BJ, Jensen K, Mackey A, Weber MJ, Gioeli D.

Mol Cancer Ther. 2012 Nov;11(11):2505-15. doi: 10.1158/1535-7163.MCT-12-0461. Epub 2012 Sep 7.

13.

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.

Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, Holemon H, Gioeli D.

PLoS One. 2012;7(6):e38950. doi: 10.1371/journal.pone.0038950. Epub 2012 Jun 27.

14.

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF 3rd, Conaway M, Weber MJ.

Mol Cancer Ther. 2011 Sep;10(9):1581-90. doi: 10.1158/1535-7163.MCT-10-1033. Epub 2011 Jun 28.

15.

MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.

Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG, Freeman MR.

Cancer Res. 2011 Jun 15;71(12):4303-13. doi: 10.1158/0008-5472.CAN-10-4532. Epub 2011 Apr 21.

16.

CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D.

Mol Endocrinol. 2010 Dec;24(12):2267-80. doi: 10.1210/me.2010-0238. Epub 2010 Oct 27.

17.

Matrix rigidity regulates cancer cell growth and cellular phenotype.

Tilghman RW, Cowan CR, Mih JD, Koryakina Y, Gioeli D, Slack-Davis JK, Blackman BR, Tschumperlin DJ, Parsons JT.

PLoS One. 2010 Sep 23;5(9):e12905. doi: 10.1371/journal.pone.0012905.

18.

Karyopherin alpha7 (KPNA7), a divergent member of the importin alpha family of nuclear import receptors.

Kelley JB, Talley AM, Spencer A, Gioeli D, Paschal BM.

BMC Cell Biol. 2010 Aug 11;11:63. doi: 10.1186/1471-2121-11-63.

19.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

20.

FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.

Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM.

Mol Cell Biol. 2010 Mar;30(5):1243-53. doi: 10.1128/MCB.01891-08. Epub 2010 Jan 4.

Supplemental Content

Loading ...
Support Center